Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Publication

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Journal Paper/Review - Aug 10, 2023

Bandini Cecilia, Mereu Elisabetta, Paradzik Tina, Labrador Maria, Maccagno Monica, Cumerlato Michela, Oreglia Federico, Prever Lorenzo, Manicardi Veronica, Taiana Elisa, Ronchetti Domenica, D'Agostino Mattia, Gay Francesca, Larocca Alessandra, Besse Lenka, Merlo Giorgio Roberto, Hirsch Emilio, Ciarrocchi Alessia, Inghirami Giorgio Ga, Neri Antonino, Piva Roberto

Citation

Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo G, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol 2023; 12:71.

Type

Journal Paper/Review (English)

Journal

Exp Hematol Oncol 2023; 12

Publication Date

Aug 10, 2023

Issn Print

2162-3619

Brief description/objective

Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and disease progression remain common. Therefore, a major challenge is the development of novel therapeutic approaches to overcome drug resistance, improve patient outcomes, and broaden PIs applicability to other pathologies.